MarketBeat
23 Sept 2026, 04:02 UTC · 2h ago
Verdict
Headline takes no side. We score NBIX +0.20 across five claims — slightly bullish.
+0.20slightly bullish
More positive than 52% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish · 0 new · 5 priced in
INGREZZA revenue is expected to decline in 2029 due to a Medicare maximum fair price discount estimated between 25% and 34%.
Priced indiscussion during a Morgan Stanley event
So whatGiven 2026 guidance of ~$2.85B, a ~30% hit to Medicare revenue in 2029 creates a significant cliff for EPS unless pipeline assets fill the gap.
More negative than 95% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
CRENESSITY has reached an annualized revenue run rate of approximately $750 million.
Priced indiscussion during a Morgan Stanley event
So whatThis represents roughly 26% of the 2026 projected INGREZZA revenue, diversifying the company's top-line concentration.
More positive than 77% of claims this week
Neurocrine expects a Medicare Part D catastrophic-phase rebate increase from 2% to 5% in 2027.
Priced indiscussion during a Morgan Stanley event
So whatThis 300bps margin headwind hits in FY2027, coinciding with the first year of a competitor's negotiated price.
More negative than 78% of claims this week
VYKAT XR has an annualized run rate of about $400 million with a 20% to 25% discontinuation rate over one year.
Priced indiscussion during a Morgan Stanley event
More negative than 70% of claims this week
A Phase II study for CRENESSITY in children ages three months to under four years is expected to yield data in 2028.
Priced indiscussion during a Morgan Stanley event
So whatPositive results would expand the addressable market beyond the current pediatric population (which is currently ~33% of users).
More positive than 51% of claims this week
Which stocks this story touches
More positive than 52% of ticker scores this week
Positive updates on product growth, AI adoption, and pipeline, though tempered by future Medicare price negotiation headwinds for INGREZZA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
NBIX hasn't traded since this ran. Last close $142.25 (Sep 22); the reaction starts at the next open.
NBIX chart →